Amendment and Response

Serial No.: 09/641,802 Confirmation No.: 5387 Filed: August 17, 2000

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF TO

PROMOTE NEURONAL CELL DIFFERENTIATION

aligning the residues of the two amino acid sequences to optimize the number of identical amino acids along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of identical amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. Preferably, two amino acid sequences are compared using the Blastp program, version 2.0.9, of the BLAST 2 search algorithm, available on the worldwide web at ncbi.nlm.nih.gov/gorf/b12.html.

Preferably, the default values for all BLAST 2 search parameters are used, including matrix = BLOSUM62; open gap penalty = 11, extension gap penalty = 1, gap x_dropoff = 50, expect = 10, wordsize = 3, and filter on. In the comparison of two amino acid sequences using the BLAST search algorithm, structural similarity is referred to as "identity." Preferably, an active analog of colostrinin or its constituent peptides has a structural similarity to colostrinin or one or more of its constituent peptides (preferably, one of SEQ ID NOs:1-34) of at least about 70% identity, more preferably, at least about 80% identity, and most preferably, at least about 90% identity.

Please replace the paragraph beginning at page 3, line 9, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

B3

In other embodiments, the invention provides the use of a neural cell regulator in the manufacture of a medicament for use in the methods described herein.

Please replace the paragraph beginning at page 8, line 10, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

Amendment and Response

Serial No.: 09/641,802 Confirmation No.: 5387 Filed: August 17, 2000

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF TO

PROMOTE NEURONAL CELL DIFFERENTIATION

The polypeptides of SEQ ID NOs:1-34 can be in their free acid form or they can be amidated at the C-terminal carboxylate group. The present invention also includes analogs of the polypeptides of SEQ ID NOs:1-34, which includes polypeptides having structural similarity with SEQ ID NOs:1-34. These peptides can also form a part of a larger peptide. An "analog" of a polypeptide includes at least a portion of the polypeptide, wherein the portion contains deletions or additions of one or more contiguous or noncontiguous amino acids, or containing one or more amino acid substitutions. An "analog" can thus include additional amino acids at one or both of the termini of the polypeptides listed above. Substitutes for an amino acid in the polypeptides of the invention are preferably conservative substitutions, which are selected from other members of the class to which the amino acid belongs. For example, it is well-known in the art of protein biochemistry that an amino acid belonging to a grouping of amino acids having a particular size or characteristic (such as charge, hydrophobicity, and hydrophilicity) can generally be substituted for another amino acid without substantially altering the structure of a polypeptide.

In the Claims

Please amend claims 1, 6-9, and 11-15. The amended claims are provided below in clean form. Per 37 C.F.R. §1.121, amended claims are also shown in Appendix A with notations to indicate changes made (for convenience, all pending claims are provided in Appendix A).



1. [AMENDED] A method for promoting cell differentiation, the method comprising contacting cells with a neuronal cell regulator selected from the group of colostrinin, a constituent peptide thereof, an active analog thereof, and combinations thereof, under conditions effective to change the cells in morphology to form neuronal cells; wherein the active analog comprises a peptide having an amino acid sequence with at least about 15 percent proline and